Phosphonyl ester conjugates as prodrugs
AssigneesTSRL, Inc., National Institute of Health (NIH), The United States of America as represented by the Department of Health and Human Services (DHHS), The United States of America as represented by NIH Division of Extramural Inventions and Technology Resources (DEITR)
InventorsJohn Hilfinger, Charles E. McKenna, Boris A. Kashemirov, Chi Pham, Kanokkarn Saejueng, Larryn Peterson
Life of this patent
Estimating the term…
Abstract
Cidofovir or foscarnet based compounds having an amino acid or dipeptide esters are provided as prodrugs.
Claims7
A prodrug compound
- where Nt is
- Q is O or S;
- R3 is —(CH2)n—, —CHCH3(CH2)n—, or —(C6H4)(CH2)n;
- R4 is O-isopropyl, O-isobutyl, O-tert-butyl, 0-2-tert-pentyl, —O—(CH2)n—C6R510, —O—(CH2)n—CH—(C6R510)2, —O—(CH2)nC(C6R510)3, or —O—C5N′R510;
- n is independently in each occurrence an integer between 0 and 12;
- R10 is independently in each occurrence H, F, Cl, Br, C1-C4 alkyl, C0-C4 primary amine, C0-C4 amine having one or two C1-C8 alkyl substituents, C0-C4 hydroxyl, C0-C4 carboxyl, C0-C4 sulfonate, and a quaternary amine or
- R5 is H, or
- R6 is an amino acid side chain of —H, —NH2, —C1-5 alkyl, —C1-5 alkanol, —C1-5 alkyl carboxylic acid, —C1-5 alkyl amine, —C1-5 alkyl amide, —C1-5 alkyl imine, —C1-5 alkyl delta-guanido and -methylphenyl;
- and R7 is —O-isopropyl, —O-isobutyl, —O-tert-butyl, —O-isopentyl or —O-2-tert-pentyl;
- C* is either a R- or S-chiral carbon atom;
- and L is a nullity or a linker a group of C1-C8 alkyl, C1-C8 alkyl having a pendent heteroatom containing moiety of O, N or S present as a carboxyl, carbonyl, hydroxyl, amino, amido, sulfonyl, or quaternary amino.
A cidofovir compound having the structure of various valine-serine isopropyl esters of cidofovir and various threonine esters of cyclic cidofovir.
A prodrug compound
- where R8 in each occurrence is OH, OR9,
- Q is O or S;
- R3 is —(CH2)n—, —CHCH3(CH2)n—, or —(C6H4)(CH2)n;
- n is independently in each occurrence an integer between 0 and 12;
- R10 is independently in each occurrence H, F, Cl, Br, C1-C4 alkyl, C0-C4 primary amine, C0-C4 amine having one or two C1-C8 alkyl substituents, C0-C4 hydroxyl, C0-C4 carboxyl, C0-C4 sulfonate, and a quaternary amine or
- R5 is H, or
- R6 is an amino acid side chain of —H, —NH2, —C1-5 alkyl, —C1-5 alkanol, —C1-5 alkyl carboxylic acid, —C1-5 alkyl amine, —C1-5 alkyl amide, —C1-5 alkyl imine, —C1-5 alkyl delta-guanido and -methylphenyl;
- and R5 is isopropyl, isobutyl, tert-butyl, or isopentyl or 2-tert-pentyl;
- C* is either a R- or S-chiral carbon atom;
- and L is a nullity or a linker a group of C1-C8 alkyl, C1-C8 alkyl having a pendent heteroatom containing moiety of O, N or S present as a carboxyl, carbonyl, hydroxyl, amino, amido, sulfonyl, or quaternary amino;
- and R7 is a C1-C5 alkyl, —(CH2)n—C6R58, —(CH2)n—CH—(C6R58)2, —(CH2)nC(C6R58)3, or —C5N′R58.
An inventive prodrug compound of the formula:
- where R3 is —(CH2)n—, —CHCH3(CH2)n, and
- —(C6H4)(CH2)n;
- R4 is O-isopropyl, O-isobutyl, O-tert-butyl or O-2-tert-pentyl,
- —O—(CH2)n—C6R510, —O—(CH2)n—CH—(C6R510)2, —O—(CH2)nC(C6R510)3, and —O—C5N′R510;
- n is independently in each occurrence an integer between 0 and 12;
- R10 is independently in each occurrence H, F, Cl, Br, C1-C4 alkyl, C0-C4 primary amine, C0-C4 amine having one or two C1-C8 alkyl substituents, C0-C4 hydroxyl, C0-C4 carboxyl, C0-C4 sulfonate, and a quaternary amine or
- R5 is H, or
- R6 is an amino acid side chain of —H, —NH2, —C1-5 alkyl, —C1-5 alkanol, —C1-5 alkyl carboxylic acid, —C1-5 alkyl amine, —C1-5 alkyl amide, —C1-5 alkyl imine, —C1-5 alkyl delta-guanido and -methylphenyl;
- and R7 is —O-isopropyl, —O-isobutyl, —O-tert-butyl, —O-isopentyl or —O-2-tert-pentyl;
- and C* is either a R- or S-chiral carbon atom. L is a nullity or a linker a group of C1-C8 alkyl, C1-C8 alkyl having a pendent heteroatom containing moiety of O, N or S present as a carboxyl, carbonyl, hydroxyl, amino, amido, sulfonyl, or quaternary amino. It is appreciated that a radioisotope or spectroscopically active label is readily added as a pendent moiety to the linker L.
Dependencies are inferred from the claim text.